KR20030007501A - 내성 유방암 치료에서의 풀베스트란트의 용도 - Google Patents
내성 유방암 치료에서의 풀베스트란트의 용도 Download PDFInfo
- Publication number
- KR20030007501A KR20030007501A KR1020027013366A KR20027013366A KR20030007501A KR 20030007501 A KR20030007501 A KR 20030007501A KR 1020027013366 A KR1020027013366 A KR 1020027013366A KR 20027013366 A KR20027013366 A KR 20027013366A KR 20030007501 A KR20030007501 A KR 20030007501A
- Authority
- KR
- South Korea
- Prior art keywords
- treatment
- fulvestrant
- breast cancer
- lesions
- patients
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 97
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 title claims abstract description 59
- 229960002258 fulvestrant Drugs 0.000 title claims abstract description 54
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 42
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 34
- 239000003886 aromatase inhibitor Substances 0.000 claims abstract description 22
- 239000000333 selective estrogen receptor modulator Substances 0.000 claims abstract description 20
- 229940095743 selective estrogen receptor modulator Drugs 0.000 claims abstract description 18
- 229940046844 aromatase inhibitors Drugs 0.000 claims abstract description 10
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 15
- 229960001603 tamoxifen Drugs 0.000 claims description 14
- 229940122815 Aromatase inhibitor Drugs 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical group N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims description 10
- 229960002932 anastrozole Drugs 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000003902 lesion Effects 0.000 description 55
- 230000004044 response Effects 0.000 description 44
- 206010028980 Neoplasm Diseases 0.000 description 31
- 201000010099 disease Diseases 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 230000000694 effects Effects 0.000 description 21
- 239000000203 mixture Substances 0.000 description 21
- 206010061818 Disease progression Diseases 0.000 description 20
- 230000005750 disease progression Effects 0.000 description 20
- 238000002474 experimental method Methods 0.000 description 19
- 238000002591 computed tomography Methods 0.000 description 18
- 238000011156 evaluation Methods 0.000 description 18
- 206010061728 Bone lesion Diseases 0.000 description 17
- 238000009472 formulation Methods 0.000 description 17
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 15
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 15
- 102000015694 estrogen receptors Human genes 0.000 description 13
- 108010038795 estrogen receptors Proteins 0.000 description 13
- 238000007469 bone scintigraphy Methods 0.000 description 12
- 230000036961 partial effect Effects 0.000 description 12
- 239000000262 estrogen Substances 0.000 description 11
- 238000002595 magnetic resonance imaging Methods 0.000 description 11
- 229940011871 estrogen Drugs 0.000 description 10
- 239000000328 estrogen antagonist Substances 0.000 description 10
- JBTWLSYIZRCDFO-UHFFFAOYSA-N ethyl methyl carbonate Chemical compound CCOC(=O)OC JBTWLSYIZRCDFO-UHFFFAOYSA-N 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- 229940046836 anti-estrogen Drugs 0.000 description 9
- 230000001833 anti-estrogenic effect Effects 0.000 description 9
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 9
- 229940122361 Bisphosphonate Drugs 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 150000004663 bisphosphonates Chemical class 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 229960003881 letrozole Drugs 0.000 description 8
- 210000000038 chest Anatomy 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 230000002018 overexpression Effects 0.000 description 7
- 239000000825 pharmaceutical preparation Substances 0.000 description 7
- 238000001959 radiotherapy Methods 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 108700012941 GNRH1 Proteins 0.000 description 6
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 6
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 6
- 230000002611 ovarian Effects 0.000 description 6
- 230000009885 systemic effect Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 206010027476 Metastases Diseases 0.000 description 5
- 206010066901 Treatment failure Diseases 0.000 description 5
- 229960003437 aminoglutethimide Drugs 0.000 description 5
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 229940087861 faslodex Drugs 0.000 description 5
- 238000010255 intramuscular injection Methods 0.000 description 5
- 239000007927 intramuscular injection Substances 0.000 description 5
- 230000009401 metastasis Effects 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 4
- 108010082126 Alanine transaminase Proteins 0.000 description 4
- 208000020084 Bone disease Diseases 0.000 description 4
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000003054 hormonal effect Effects 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 238000003364 immunohistochemistry Methods 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 208000037821 progressive disease Diseases 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000002271 resection Methods 0.000 description 4
- 238000002604 ultrasonography Methods 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 206010006002 Bone pain Diseases 0.000 description 3
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 3
- 229960002903 benzyl benzoate Drugs 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 230000005713 exacerbation Effects 0.000 description 3
- 238000013401 experimental design Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000001794 hormone therapy Methods 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 210000004197 pelvis Anatomy 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 229940066675 ricinoleate Drugs 0.000 description 3
- WBHHMMIMDMUBKC-QJWNTBNXSA-M ricinoleate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O WBHHMMIMDMUBKC-QJWNTBNXSA-M 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 230000002618 waking effect Effects 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 206010055113 Breast cancer metastatic Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010061998 Hepatic lesion Diseases 0.000 description 2
- 206010027457 Metastases to liver Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000005250 Spontaneous Fractures Diseases 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 238000013176 antiplatelet therapy Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 238000011976 chest X-ray Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 238000009164 estrogen replacement therapy Methods 0.000 description 2
- 239000003777 experimental drug Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 230000000010 osteolytic effect Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 102000003998 progesterone receptors Human genes 0.000 description 2
- 108090000468 progesterone receptors Proteins 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229960003656 ricinoleic acid Drugs 0.000 description 2
- WBHHMMIMDMUBKC-QJWNTBNXSA-N ricinoleic acid Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(O)=O WBHHMMIMDMUBKC-QJWNTBNXSA-N 0.000 description 2
- FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- -1 4,4,5,5,5-pentafluoropentylsulfinyl Chemical group 0.000 description 1
- DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 208000022540 Consciousness disease Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 101000889443 Homo sapiens Trefoil factor 1 Proteins 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010025102 Lung infiltration Diseases 0.000 description 1
- 206010025282 Lymphoedema Diseases 0.000 description 1
- 241000489861 Maximus Species 0.000 description 1
- 206010027452 Metastases to bone Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010034156 Pathological fracture Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 102100039175 Trefoil factor 1 Human genes 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940086756 anastrozole 1 mg Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940078010 arimidex Drugs 0.000 description 1
- 239000005667 attractant Substances 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000029499 cancer-related condition Diseases 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000031902 chemoattractant activity Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000009850 completed effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 238000009261 endocrine therapy Methods 0.000 description 1
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229940087476 femara Drugs 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940075495 isopropyl palmitate Drugs 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940080456 letrozole 2.5 mg Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000002502 lymphedema Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000005015 mediastinal lymph node Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229940085033 nolvadex Drugs 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 208000037911 visceral disease Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
제제의 부피당 x의 중량% | 제제의 1 ml중의 x의 중량 |
30%20%10%5%1% | 300 mg200 mg100 mg50 mg10 mg |
AE | 부작용 |
ALP | 알카린 페스파타제 |
ALT | 알라닌 아미노트란스페라제 |
AST | 아스파르테이트 트랜스아미나제 |
BP | 혈압 |
CR | 완전 반응 |
CRF | 상황 기록 폼 |
CT | 컴퓨터 단층 촬영 |
ER | 에스트로겐 수용체 |
ERD | 에스트로겐 수용체 하부조절제 |
FISH | 현장내 형광 하이브리드화 |
HR | 심박동수 |
INR | 국제 표준화비(응고 시간) |
LH-RH | 황체 형성 호르몬 방출 호르몬 |
LP | 국소 패토도지(pathodogy) |
MRI | 자기 공명 영상법 |
PCR | 폴리메라제 쇄 반응 |
PgR | 프로게스테론 수용체 |
PR | 부분 반응 |
SD | 안정한 질환 |
SERM | 선택성 에스트로겐 수용체 조절자 |
ULRR | 기준 범위의 상한치 |
*매달 | 3개월마다 | |||||||||
매개 변수 | 적격성 심사a | V1Mo0day1b | V2Mo129 | V3Mo2 | V4Mo 3 | V5Mo6 | V6Mo9 | V7Mo12등 | 연구치료 투약 중지 | 진행까지 |
과거 병력 | X | |||||||||
공동 치료 | X | x | x | x | x | x | x | x... | xh | |
통계학 | X | |||||||||
수반 조건 | X | x | x | x | x | x | x... | x | ||
BP, HR | x | x | x | x | x | x | x... | x | ||
중량 | x | x | x | x | x | x | x... | x | ||
혈액학 | X | xc | x | x | x | x... | x | |||
INR | X | |||||||||
생화학 | X | xc | x | x | x | x... | x | |||
수행 상태 | X | x | x | x | x | x | x | x... | x | |
흉부 X 레이 또는 CT 스캔 | Xd | |||||||||
골 스캔 | Xd | |||||||||
종양 평가 | Xd | xe | xe | xf,g | x | x | x... | x | xg | |
부작용 | x | x | x | x | x | x... | xh | |||
HER-2/neui |
등급 | |
제한이 없고, 통증이 없이 보통의 활동을 완전히 수행, 수행할 수 있는자 | 0 |
보행을 제외한 격렬한 활동에서 제한되고, 가벼운 작업을 수행할 수 있건, 좌상의 작업을 수행할 수 있는자. 또한, 이 군은 통증이 없는 경우를 제외하고, 0 등급에서와 같은 완전한 활동을 하는 환자를 포함한다. | 1 |
보행하고, 자기 간호가 가능한지만, 일을 할수 없는자. 일어나고 깨어있는 시간의 약 50% 이상인자. | 2 |
제한된 자기 간호가 가능하고, 깨어있는 시간의 50% 이상이 침대 또는 의자에 있는자. | 3 |
완전히 불가능하고, 자기 간호를 수행할 수 없고, 모든 시간에 침대 또는 의자에 있는자. | 4 |
Claims (10)
- 치료학적 유효량의 풀베스트란트를 투여하여 이전에 아로마타제 억제제로 치료하였었고, 그러한 이전의 치료를 실패한 경험이 있는 유방암 환자의 치료 방법.
- 치료학적 유효량의 풀베스트란트를 투여하여 이전에 아로마타제 억제제 및 선택적 에스트로겐 수용체 조절인자(SERM)로 치료하였었고, 그러한 이전의 치료를 실패한 경험이 있는 유방암 환자의 치료 방법.
- 제2항에 있어서, SERM을 사용한 치료가 아로마타제 억제제로의 치료보다 먼저 이루어지는 것인 방법.
- 제1항 내지 제3항중 어느 한 항에 있어서, 아로마타제 억제제는 아나스트라졸인 것인 방법.
- 제2항 내지 제4항중 어느 한 항에 있어서, SERM은 타목시펜인 것인 방법.
- 이전에 아로마타제 억제제로 치료하였었고, 그러한 이전의 치료를 실패한 경험이 있는 유방암 환자의 치료를 위한 약제의 제조에서의 풀베스트란트의 용도.
- 이전에 아로마타제 억제제 및 SERM으로 치료하였었고, 그러한 이전의 치료를 실패한 유방암 환자의 치료를 위한 약제의 제조에서의 풀베스트란트의 용도.
- 제7항에 있어서, SERM을 사용한 치료가 아로마타제 억제제를 사용한 치료보다 먼저 이루어지는 것인 용도.
- 제6항 내지 제8항중 어느 한 항에 있어서, 아로마타제 억제제는 아나스트라졸인 것인 용도.
- 제7항 내지 제9항중 어느 한 항에 있어서, SERM은 타목시펜인 것인 용도.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0008172.9 | 2000-04-05 | ||
GBGB0008172.9A GB0008172D0 (en) | 2000-04-05 | 2000-04-05 | Therapy |
PCT/GB2001/001500 WO2001074366A1 (en) | 2000-04-05 | 2001-04-02 | Use of fulvestrant in the treatment of resistant breast cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20030007501A true KR20030007501A (ko) | 2003-01-23 |
KR100757764B1 KR100757764B1 (ko) | 2007-09-12 |
Family
ID=9889101
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020027013366A KR100757764B1 (ko) | 2000-04-05 | 2001-04-02 | 내성 유방암 치료에서의 풀베스트란트의 용도 |
Country Status (29)
Country | Link |
---|---|
US (2) | US20030158166A1 (ko) |
EP (2) | EP1272195B1 (ko) |
JP (1) | JP2003528919A (ko) |
KR (1) | KR100757764B1 (ko) |
CN (1) | CN1431905A (ko) |
AT (1) | ATE306270T1 (ko) |
AU (2) | AU2001244372B2 (ko) |
BR (1) | BR0109789A (ko) |
CA (1) | CA2403608A1 (ko) |
CH (1) | CH1272195H1 (ko) |
CZ (1) | CZ303096B6 (ko) |
DE (1) | DE60113975T2 (ko) |
DK (1) | DK1272195T3 (ko) |
EE (1) | EE05026B1 (ko) |
ES (1) | ES2248300T3 (ko) |
GB (1) | GB0008172D0 (ko) |
HK (1) | HK1051498A1 (ko) |
HU (1) | HU230064B1 (ko) |
IL (2) | IL151932A0 (ko) |
IS (1) | IS2869B (ko) |
MX (1) | MXPA02009744A (ko) |
NO (1) | NO329949B1 (ko) |
NZ (1) | NZ539603A (ko) |
PL (1) | PL201175B1 (ko) |
RU (1) | RU2265438C2 (ko) |
SK (1) | SK287779B6 (ko) |
UA (1) | UA80388C2 (ko) |
WO (1) | WO2001074366A1 (ko) |
ZA (1) | ZA200207538B (ko) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0116620D0 (en) * | 2001-07-07 | 2001-08-29 | Astrazeneca Ab | Formulation |
CA2453111A1 (en) * | 2001-07-07 | 2003-01-23 | Alan Marshall Irving | Pharmaceutical formulation for the intramuscular administration of fulvestrant |
EP1623713A1 (en) * | 2004-07-09 | 2006-02-08 | Proskelia SAS | Cominations of pure anti-estrogen with aromatase inhibitors |
US8557863B2 (en) * | 2005-09-27 | 2013-10-15 | Robert Benson Aylor | Suppression and prevention of tumors |
US8324194B2 (en) * | 2005-11-22 | 2012-12-04 | Incyte Corporation | Combination therapy for the treatment of cancer |
US7910108B2 (en) * | 2006-06-05 | 2011-03-22 | Incyte Corporation | Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases |
MX2013013104A (es) * | 2011-05-09 | 2014-10-15 | Univ Virginia Patent Found | Composiciones y metodos para el tratamiento de cancer. |
MX2013013558A (es) | 2011-05-20 | 2013-12-16 | Capital Business Y Gestion De Finanzas S L | Composicion farmaceutica. |
WO2015106094A1 (en) * | 2014-01-10 | 2015-07-16 | Atossa Genetics Inc. | Transpapillary methods and compositions for diagnosing and treating breast conditions |
TWI793165B (zh) | 2017-09-11 | 2023-02-21 | 美商阿托薩醫療公司 | 製造及使用因多昔芬(endoxifen)之方法 |
AU2019274815A1 (en) * | 2018-05-24 | 2021-01-21 | Shivanka Research LLC | Prodrugs of fulvestrant |
US20230255974A1 (en) * | 2020-02-29 | 2023-08-17 | The University Of Vermont | Use of thyromimetics for the treatment of cancer |
-
2000
- 2000-04-05 GB GBGB0008172.9A patent/GB0008172D0/en not_active Ceased
-
2001
- 2001-02-04 UA UA2002118734A patent/UA80388C2/uk unknown
- 2001-04-02 MX MXPA02009744A patent/MXPA02009744A/es active IP Right Grant
- 2001-04-02 RU RU2002129355/14A patent/RU2265438C2/ru active
- 2001-04-02 EP EP01917289A patent/EP1272195B1/en not_active Expired - Lifetime
- 2001-04-02 AU AU2001244372A patent/AU2001244372B2/en not_active Expired
- 2001-04-02 AU AU4437201A patent/AU4437201A/xx active Pending
- 2001-04-02 BR BR0109789-0A patent/BR0109789A/pt not_active Application Discontinuation
- 2001-04-02 DE DE60113975T patent/DE60113975T2/de not_active Expired - Lifetime
- 2001-04-02 CH CH01917289T patent/CH1272195H1/de unknown
- 2001-04-02 NZ NZ539603A patent/NZ539603A/en not_active IP Right Cessation
- 2001-04-02 WO PCT/GB2001/001500 patent/WO2001074366A1/en active IP Right Grant
- 2001-04-02 IL IL15193201A patent/IL151932A0/xx active IP Right Grant
- 2001-04-02 PL PL357936A patent/PL201175B1/pl unknown
- 2001-04-02 US US10/240,656 patent/US20030158166A1/en not_active Abandoned
- 2001-04-02 CZ CZ20023309A patent/CZ303096B6/cs not_active IP Right Cessation
- 2001-04-02 EP EP05007561A patent/EP1586323A1/en not_active Withdrawn
- 2001-04-02 JP JP2001572110A patent/JP2003528919A/ja active Pending
- 2001-04-02 CN CN01810539A patent/CN1431905A/zh active Pending
- 2001-04-02 ES ES01917289T patent/ES2248300T3/es not_active Expired - Lifetime
- 2001-04-02 SK SK1429-2002A patent/SK287779B6/sk not_active IP Right Cessation
- 2001-04-02 DK DK01917289T patent/DK1272195T3/da active
- 2001-04-02 KR KR1020027013366A patent/KR100757764B1/ko active IP Right Grant
- 2001-04-02 CA CA002403608A patent/CA2403608A1/en not_active Abandoned
- 2001-04-02 EE EEP200200574A patent/EE05026B1/xx unknown
- 2001-04-02 AT AT01917289T patent/ATE306270T1/de active
- 2001-04-02 HU HU0300339A patent/HU230064B1/hu unknown
-
2002
- 2002-09-19 ZA ZA200207538A patent/ZA200207538B/en unknown
- 2002-09-25 IL IL151932A patent/IL151932A/en unknown
- 2002-10-01 IS IS6576A patent/IS2869B/is unknown
- 2002-10-02 NO NO20024735A patent/NO329949B1/no not_active IP Right Cessation
-
2003
- 2003-05-27 HK HK03103770A patent/HK1051498A1/xx not_active IP Right Cessation
-
2010
- 2010-09-30 US US12/895,369 patent/US20110183949A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20110183949A1 (en) | Use of Fulvestrant in the Treatment of Resistant Breast Cancer | |
Paridaens et al. | Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer | |
Ellis et al. | Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study | |
KIANG et al. | Tamoxifen (antiestrogen) therapy in advanced breast cancer | |
Reginster et al. | Minimal levels of serum estradiol prevent postmenopausal bone loss | |
Bajetta et al. | Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients | |
Emons et al. | Phase II study of fulvestrant 250 mg/month in patients with recurrent or metastatic endometrial cancer: A study of the Arbeitsgemeinschaft Gynäkologische Onkologie | |
Lee et al. | Local Transdermal Delivery of Telapristone Acetate Through Breast Skin, Compared With Oral Treatment: A Randomized Double‐Blind, Placebo‐Controlled Phase II Trial | |
AU2001244372A1 (en) | Use of fulvestrant in the treatment of resistant breast cancer | |
Hirvonen et al. | Can progestin be limited to every third month only in postmenopausal women taking estrogen? | |
HRP20120084A2 (hr) | FULVESTRANT U DOZI OD 500 mg ZA LIJEČENJE UZNAPREDOVALOG RAKA DOJKE | |
RU2320339C2 (ru) | Применение анастрозола для лечения женщин в постклимактерическом периоде, которые страдают ранним раком молочной железы | |
Manni et al. | Transsphenoidal hypophysectomy in breast cancer. Evidence for an individual role of pituitary and gonadal hormones in supporting tumor growth. | |
Homesley et al. | Antiestrogenic potency of toremifene and tamoxifen in postmenopausal women | |
Goss et al. | Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer | |
Williams et al. | Multicenter study of trilostane: a new hormonal agent in advanced postmenopausal breast cancer. | |
Bezwoda et al. | Fadrozole versus megestrol acetate: a double-blind randomised trial in advanced breast cancer | |
Zilembo et al. | The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients | |
WO2023175477A1 (en) | Treatment of breast cancer with amcenestrant | |
Howell et al. | Endocrine therapy | |
Smith | Endocrine aspects of breast cancer | |
VICARIO et al. | Clinical and endocrine effects of megestrol-acetate in women with pretreated advanced breast-cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
G170 | Re-publication after modification of scope of protection [patent] | ||
FPAY | Annual fee payment |
Payment date: 20120821 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20130820 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20140825 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20150818 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20160818 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20170818 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20180816 Year of fee payment: 12 |